○Shuntaro Shimizu1, Tomoya Hayashi1,2,3, Koji Sakamoto4, Naozumi Hashimoto5, Kouji Kobiyama1,2,3, Hideo Negishi1,2, Brucu Temizoz1,2,3, Cevayir Coban2,6, Ken J Ishii1,2,3
(1.Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan, 2.International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan, 3.Laboratory of Adjuvant Innovation, Center for Vaccine and Adjuvant Research (CVAR), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan, 4.Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan, 5.Department of Respiratory Medicine, Fujita Health University, Nagoya, Japan, 6.Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan)
抄録パスワード認証
抄録を閲覧するためにはパスワードを入力してください。
参加登録をされた方に8月28日(月)<予定>に運営事務局よりメールでお知らせいたします。